

Improvement of Prostate Cancer Diagnosis by Detecting Changes

Theranostics

6, 1190-1204

DOI: [10.7150/thno.15226](https://doi.org/10.7150/thno.15226)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer. <i>Epigenetics</i> , 2016, 11, 845-857.	1.3	39
2	Lectin-based lateral flow assay: proof-of-concept. <i>Analyst, The</i> , 2016, 141, 6444-6448.	1.7	25
3	Glycosylation is a global target for androgen control in prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2017, 24, R49-R64.	1.6	53
4	The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. <i>European Urology</i> , 2017, 72, 942-949.	0.9	35
5	Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer. <i>Clinica Chimica Acta</i> , 2017, 470, 97-102.	0.5	10
6	Site-Specific Fucosylation Analysis Identifying Glycoproteins Associated with Aggressive Prostate Cancer Cell Lines Using Tandem Affinity Enrichments of Intact Glycopeptides Followed by Mass Spectrometry. <i>Analytical Chemistry</i> , 2017, 89, 7623-7630.	3.2	65
7	Sialic acid linkage differentiation of glycopeptides using capillary electrophoresis "electrospray ionization" mass spectrometry. <i>Scientific Reports</i> , 2017, 7, 3733.	1.6	82
8	Label-free chronopotentiometric glycoprofiling of prostate specific antigen using sialic acid recognizing lectins. <i>Bioelectrochemistry</i> , 2017, 117, 89-94.	2.4	33
9	Sample preparation of serum to allow capillary electrophoresis analysis of prostate specific antigen isoforms. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 134, 220-227.	1.4	6
10	Nanotechnology as a Delivery Tool for Precision Cancer Therapies. <i>AAPS Journal</i> , 2017, 19, 1632-1642.	2.2	9
11	Shifted Golgi targeting of glycosyltransferases and α -mannosidase IA from giantin to GM130-GRASP65 results in formation of high mannose N-glycans in aggressive prostate cancer cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2891-2901.	1.1	18
12	Current advances and future visions on bioelectronic immunosensing for prostate-specific antigen. <i>Biosensors and Bioelectronics</i> , 2017, 98, 267-284.	5.3	42
13	Comparative analysis of prostate-specific antigen by two-dimensional gel electrophoresis and capillary electrophoresis. <i>Electrophoresis</i> , 2017, 38, 408-416.	1.3	6
14	An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α 2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 470.	1.8	37
15	Comparative Study of Blood-Based Biomarkers, α 2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. <i>International Journal of Molecular Sciences</i> , 2017, 18, 845.	1.8	41
16	PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis. <i>Journal of Cancer</i> , 2017, 8, 1223-1228.	1.2	10
17	Lectins: an effective tool for screening of potential cancer biomarkers. <i>PeerJ</i> , 2017, 5, e3784.	0.9	77
18	Advances in Biomarkers for PCa Diagnostics and Prognostics" A Way towards Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2193.	1.8	6

#	ARTICLE	IF	CITATIONS
19	An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen. <i>Analytical Chemistry</i> , 2018, 90, 4414-4421.	3.2	54
20	An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example. <i>Clinica Chimica Acta</i> , 2018, 480, 1-8.	0.5	14
21	Serum sialylation changes in cancer. <i>Glycoconjugate Journal</i> , 2018, 35, 139-160.	1.4	127
22	An electrochemical approach capable of prostate specific antigen assay in human serum based on exonuclease-aided target recycling amplification. <i>Sensors and Actuators B: Chemical</i> , 2018, 257, 1021-1026.	4.0	26
23	Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera. <i>Scientific Reports</i> , 2018, 8, 6509.	1.6	38
24	Glycan affinity magnetic nanoplateforms for urinary glycobiomarkers discovery in bladder cancer. <i>Talanta</i> , 2018, 184, 347-355.	2.9	29
25	Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. <i>Cellular Immunology</i> , 2018, 333, 46-57.	1.4	157
26	Sweet Strategies in Prostate Cancer Biomarker Research: Focus on a Prostate Specific Antigen. <i>BioNanoScience</i> , 2018, 8, 690-700.	1.5	12
27	Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer. <i>Analytical Chemistry</i> , 2018, 90, 208-224.	3.2	64
28	Alteration of glycosylation in serum proteins: a new potential indicator to distinguish non-diabetic renal diseases from diabetic nephropathy. <i>RSC Advances</i> , 2018, 8, 38872-38882.	1.7	5
29	IMass Time: The Future, in Future!. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 679-695.	1.0	13
30	A historical cohort study on glycemic-control and cancer-risk among patients with diabetes. <i>Cancer Epidemiology</i> , 2018, 57, 104-109.	0.8	20
32	The trimeric solution structure and fucose-binding mechanism of the core fucosylation-specific lectin PhoSL. <i>Scientific Reports</i> , 2018, 8, 7740.	1.6	14
33	Recognition of Complex Core α -Fucosylated N-glycans by a Mini Lectin. <i>Angewandte Chemie</i> , 2018, 130, 10335-10338.	1.6	2
34	Recognition of Complex Core α -Fucosylated N-glycans by a Mini Lectin. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 10178-10181.	7.2	15
35	Emerging biomarkers in the diagnosis of prostate cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 83-94.	0.4	71
36	Glycosylation products in prostate diseases. <i>Clinica Chimica Acta</i> , 2019, 498, 52-61.	0.5	10
37	Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA. <i>Analytical Chemistry</i> , 2019, 91, 2247-2254.	3.2	42

#	ARTICLE	IF	CITATIONS
38	The construction of electrochemical aptasensor based on coral-like poly-aniline and Au nano-particles for the sensitive detection of prostate specific antigen. <i>Sensors and Actuators B: Chemical</i> , 2019, 295, 93-100.	4.0	48
39	Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities. <i>Nature Reviews Urology</i> , 2019, 16, 433-445.	1.9	24
40	Core fucosylated glycan-dependent inhibitory effect of QSOX1-S on invasion and metastasis of hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2019, 5, 84.	2.0	12
41	Glycans as Biomarkers in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1389.	1.8	80
42	Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness. <i>Tumor Biology</i> , 2019, 41, 101042831982722.	0.8	10
43	Structural basis for specific recognition of core fucosylation in N-glycans by Phlojota squarrosa lectin (PhoSL). <i>Glycobiology</i> , 2019, 29, 576-587.	1.3	8
44	Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. <i>Interface Focus</i> , 2019, 9, 20180077.	1.5	53
46	Capillary Electrophoresis Analysis of Prostate-Specific Antigen (PSA). <i>Methods in Molecular Biology</i> , 2019, 1972, 221-234.	0.4	1
47	Glycomics of prostate cancer: updates. <i>Expert Review of Proteomics</i> , 2019, 16, 65-76.	1.3	25
48	Deciphering Protein Glycosylation by Computational Integration of On-chip Profiling, Glycan-array Data, and Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 28-40.	2.5	15
49	Recent Advances in Glycoproteomic Analysis by Mass Spectrometry. <i>Analytical Chemistry</i> , 2020, 92, 267-291.	3.2	96
50	Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100831.	2.7	9
51	Mass spectrometry in clinical glycomics: The path from biomarker identification to clinical implementation. <i>Clinical Mass Spectrometry</i> , 2020, 18, 1-12.	1.9	17
52	Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies. <i>Cancers</i> , 2020, 12, 2988.	1.7	16
53	Three-dimensional biosensor surface based on novel thorns-like polyelectrolytes. <i>Biosensors and Bioelectronics</i> , 2020, 167, 112504.	5.3	4
54	Characterisation of the main PSA glycoforms in aggressive prostate cancer. <i>Scientific Reports</i> , 2020, 10, 18974.	1.6	17
55	Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms. <i>Glycoconjugate Journal</i> , 2020, 37, 703-711.	1.4	9
56	HILIC-MRM-MS for Linkage-Specific Separation of Sialylated Glycopeptides to Quantify Prostate-Specific Antigen Proteoforms. <i>Journal of Proteome Research</i> , 2020, 19, 2708-2716.	1.8	27

#	ARTICLE	IF	CITATIONS
57	Aptamers in nanostructure-based electrochemical biosensors for cardiac biomarkers and cancer biomarkers: A review. <i>Biosensors and Bioelectronics</i> , 2020, 152, 112018.	5.3	101
58	Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. <i>Theranostics</i> , 2020, 10, 4903-4928.	4.6	39
59	Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLex) in pancreatic adenocarcinoma. <i>Journal of Proteomics</i> , 2021, 231, 104004.	1.2	6
60	Impedimetric aptamer-based glycan PSA score for discrimination of prostate cancer from other prostate diseases. <i>Biosensors and Bioelectronics</i> , 2021, 175, 112872.	5.3	38
61	Separation based characterization methods for the N-glycosylation analysis of prostate-specific antigen. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 194, 113797.	1.4	7
62	Enhancing Comprehensive Analysis of Secreted Glycoproteins from Cultured Cells without Serum Starvation. <i>Analytical Chemistry</i> , 2021, 93, 2694-2705.	3.2	15
63	Capillary electrophoresis of glycoproteins. , 2021, , 645-727.		1
64	A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. <i>Theranostics</i> , 2021, 11, 6214-6224.	4.6	13
65	Glycosylated biomarker sensors: advancements in prostate cancer diagnosis. <i>Chemical Communications</i> , 2021, 57, 9640-9655.	2.2	8
66	Post-Translational Modifications That Drive Prostate Cancer Progression. <i>Biomolecules</i> , 2021, 11, 247.	1.8	21
67	Serum coreâ€¢type fucosylated prostateâ€¢specific antigen index for the detection of highâ€¢risk prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 3111-3118.	2.3	12
68	Tissue <i>N</i>-</i>linked glycosylation as potential prognostic biomarker for biochemical recurrence-free survival. <i>Biomarkers</i> , 2021, 26, 275-285.	0.9	2
69	Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 25-43.	3.0	14
70	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. <i>Journal of Personalized Medicine</i> , 2021, 11, 664.	1.1	11
71	Glycosylation: Rising Potential for Prostate Cancer Evaluation. <i>Cancers</i> , 2021, 13, 3726.	1.7	10
72	Inflammatory metabolic profile of South African patients with prostate cancer. <i>Cancer & Metabolism</i> , 2021, 9, 29.	2.4	16
73	Systematic Optimisation of Microtiter Plate Lectin Assay to Improve Sialic Acid Linkage Detection. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 24, .	0.6	0
74	Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1211-1220.	0.4	1

#	ARTICLE	IF	CITATIONS
75	Lectins applied to diagnosis and treatment of prostate cancer and benign hyperplasia: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 190, 543-553.	3.6	4
76	A glycan-based plasmonic sensor for prostate cancer diagnosis. <i>Analyst, The</i> , 2021, 146, 6852-6860.	1.7	2
77	Clinical Validation of IsoPSA [®] , a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 1115-1120.	0.2	13
78	Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia. <i>Oncotarget</i> , 2017, 8, 76987-76999.	0.8	14
79	Distinct urinary glycoprotein signatures in prostate cancer patients. <i>Oncotarget</i> , 2018, 9, 33077-33097.	0.8	33
80	Advances in the discovery of novel biomarkers for cancer: spotlight on protein N-glycosylation. <i>Biomarkers in Medicine</i> , 2020, 14, 1031-1045.	0.6	8
81	Prostate Cancer Detection: Complexities and Strategies. <i>Journal of Cancer Treatment & Diagnosis</i> , 2017, 2, 18-25.	0.9	9
82	Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 2537-2554.	1.4	30
83	Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue. <i>Prostate</i> , 2022, 82, 132-144.	1.2	3
84	Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA and Prostate Cancer. <i>Methods in Molecular Biology</i> , 2022, 2370, 301-313.	0.4	2
85	Modern urology perspectives on prostate cancer biomarkers. <i>Central European Journal of Urology</i> , 2018, 71, 420-426.	0.2	9
86	Label-free PSA electrochemical determination by seed-mediated electrochemically-deposited gold nanoparticles on an FTO electrode. <i>Journal of Solid State Electrochemistry</i> , 2022, 26, 149-161.	1.2	8
87	Abnormal sialylation and fucosylation of saliva glycoproteins: Characteristics of lung cancer-specific biomarkers. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100079.	1.7	12
88	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. <i>International Journal of Transgender Health</i> , 2022, 15, 378-433.	1.1	2
89	Glycosylation Changes in Prostate Cancer Progression. <i>Frontiers in Oncology</i> , 2021, 11, 809170.	1.3	18
90	Advances in glycopeptide enrichment methods for the analysis of protein glycosylation over the past decade. <i>Journal of Separation Science</i> , 2022, 45, 3169-3186.	1.3	18
91	Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients'™ Sera. <i>Biomedicines</i> , 2022, 10, 1942.	1.4	1
93	Prediction of gastric cancer by machine learning integrated with mass spectrometry-based N-glycomics. <i>Analyst, The</i> , 2023, 148, 2073-2080.	1.7	5

#	ARTICLE	IF	CITATIONS
94	The hidden potential of glycomarkers: Glycosylation studies in the service of cancer diagnosis and treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188889.	3.3	5
95	Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection. <i>Nature Communications</i> , 2023, 14, .	5.8	6
96	Aberrant protein glycosylation: Implications on diagnosis and Immunotherapy. <i>Biotechnology Advances</i> , 2023, 66, 108149.	6.0	9
97	Human Prostate-Specific Antigen Carries N-Glycans with Ketodeoxynononic Acid. <i>Engineering</i> , 2023, 26, 119-131.	3.2	1